EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients

Bin Jia, Peiyi Xia, Junqiang Dong, Wenhao Feng, Wenjia Wang, Enjie Liu, Guozhong Jiang, Yanru Qin

Frontiers in Oncology · 17.01.2023 · 12

DOI: 10.3389/fonc.2022.1086908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 17.01.2023. Verfasst von Bin Jia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: First Affiliated Hospital of Zhengzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sarcomatoid hepatocellular carcinoma (SHC) is a rare epithelial malignancy with high invasiveness and poor prognosis. However, the molecular characteristics and main driver genes for SHC have not been determined. The aim of this study is to explore the potentially actionable mutations of driver genes, which may provide more therapeutic options for SHC.

Methods

In this study, DNA extraction and library preparation were performed using tumor tissues from 28 SHC patients. Then we used Miseq platform (Illumina) to sequence the target-enriched library, and we aligned and processed the sequencing data. The gene groups were tested for SNVs/Indels/CNVs. Tumor mutation burden (TMB) was assessed by the 425-cancer-relevant gene panel. Multivariate analysis of COX’s model was used for survival analysis (OS) of patients’ clinical characteristics.

Result

The median overall survival (OS) of the patients was only 4.4 months. TP53 , TERT , and KRAS were the top three frequently mutated genes, with frequencies of 89.3%, 64.3%, and 21.4%, respectively. A considerable number of patients carried mutations in genes involved in the TP53 pathway (96%) and DNA Damage Repair (DDR) pathway (21%). Multiple potentially actionable mutations, such as NTRK1 fusions and BRCA1/2 mutations, were identified in SHCs.

Conclusions

This study shows a landscape of gene mutations in SHC. SHC has high mutation rates in TP53 pathway and DDR pathway. The potentially actionable mutations of driver genes may provide more therapeutic options for SHC. Survival analysis found that age, smoking, drinking, and tumor diameter may be independent prognostic predictors of SHC.

Schlagwörter

Stichwörter der Autor:innen

gene mutationgenetic testinghepatic tumorsprognosissarcomatoid carcinoma

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
  • Department of Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Förderung

  • First Affiliated Hospital of Zhengzhou University

Zitieren

APA

Jia, B., Xia, P., Dong, J., Feng, W., Wang, W., Liu, E., Jiang, G., & Qin, Y. (2023). Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1086908

Vancouver

Jia B, Xia P, Dong J, Feng W, Wang W, Liu E, et al. Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients. Frontiers in Oncology. 2023;12. doi:10.3389/fonc.2022.1086908

BibTeX
@article{Jia2023,
  author = {Jia, Bin and Xia, Peiyi and Dong, Junqiang and Feng, Wenhao and Wang, Wenjia and Liu, Enjie and Jiang, Guozhong and Qin, Yanru},
  title = {Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients},
  journal = {Frontiers in Oncology},
  year = {2023},
  volume = {12},
  doi = {10.3389/fonc.2022.1086908}
}
Kostenlos starten →